Literature DB >> 9241116

Who uses needle exchange? A study of injection drug users in treatment in San Francisco, 1989-1990.

J A Hahn1, K M Vranizan, A R Moss.   

Abstract

We examined use of the San Francisco needle exchange program (NEP) by 1093 injection drug users (IDUs) recruited in methadone maintenance and out-patient detoxification programs in the first 2 years after the opening of the NEP in 1988. Thirty-one percent of IDUs had ever used the NEP. IDUs who were frequent injectors, homeless, and aware of their serostatus were more likely to use the NEP. To assess self-selection of IDUs at risk for seroconversion for using needle exchange, we calculated pre-needle exchange seroconversion rates. Among 385 IDUs seen twice, the HIV seroconversion rate was 0.38% per person year among subjects who never used needle exchange, but it was 9.34% per person year among those who later used needle exchange (p = 0.003). NEP attracted a subset of IDUs at very high risk for HIV infection. Among injectors who were interviewed before and after the opening of the needle exchanges in San Francisco, the number of sharing partners did not change among IDUs who attended or among IDUs who never attended the NEP. The NEP attracted a very-high-risk subgroup of IDUs, as measured by risk behavior and pre-needle exchange HIV-seroconversion rate. NEPs should be considered prime sites for behavior-change interventions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9241116     DOI: 10.1097/00042560-199706010-00010

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr Hum Retrovirol        ISSN: 1077-9450


  13 in total

1.  Volunteer bias in nonrandomized evaluations of the efficacy of needle-exchange programs.

Authors:  H Hagan; J P McGough; H Thiede; S G Hopkins; N S Weiss; E R Alexander
Journal:  J Urban Health       Date:  2000-03       Impact factor: 3.671

2.  Selection effect of needle exchange in Anchorage, Alaska.

Authors:  Dennis G Fisher; Grace L Reynolds; Colin R Harbke
Journal:  J Urban Health       Date:  2002-03       Impact factor: 3.671

Review 3.  Epidemiology and the politics of needle exchange.

Authors:  A R Moss
Journal:  Am J Public Health       Date:  2000-09       Impact factor: 9.308

4.  Sex-specific determinants of HIV infection among injection drug users in Montreal.

Authors:  J Bruneau; F Lamothe; J Soto; N Lachance; J Vincelette; A Vassal; E L Franco
Journal:  CMAJ       Date:  2001-03-20       Impact factor: 8.262

5.  Treatment readiness, attitudes toward, and experiences with methadone and buprenorphine maintenance therapy among people who inject drugs in Malaysia.

Authors:  Aishwarya Vijay; Alexander R Bazazi; Ilias Yee; Adeeba Kamarulzaman; Frederick L Altice
Journal:  J Subst Abuse Treat       Date:  2015-02-18

6.  Drug injection rates and needle-exchange use in New York City, 1991-1996.

Authors:  M Marmor; R E Shore; S Titus; X Chen; D C Des Jarlais
Journal:  J Urban Health       Date:  2000-09       Impact factor: 3.671

7.  Benefits of concurrent syringe exchange and substance abuse treatment participation.

Authors:  Michael Kidorf; Van L King; Jessica Peirce; Jessica Pierce; Ken Kolodner; Robert K Brooner
Journal:  J Subst Abuse Treat       Date:  2011-01-20

8.  Sexual relationships, secondary syringe exchange, and gender differences in HIV risk among drug injectors.

Authors:  Kara S Riehman; Alex H Kral; Rachel Anderson; Neil Flynn; Ricky N Bluthenthal
Journal:  J Urban Health       Date:  2004-06       Impact factor: 3.671

9.  A comparison of 1-year substance abuse treatment outcomes in community syringe exchange participants versus other referrals.

Authors:  Karin Neufeld; Van King; Jessica Peirce; Ken Kolodner; Robert Brooner; Michael Kidorf
Journal:  Drug Alcohol Depend       Date:  2008-05-16       Impact factor: 4.492

10.  The impact of needle-exchange programs on the spread of HIV among injection drug users: a simulation study.

Authors:  J M Raboud; M C Boily; J Rajeswaran; M V O'Shaughnessy; M T Schechter
Journal:  J Urban Health       Date:  2003-06       Impact factor: 3.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.